Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor

American Journal of Physiology - Cell Physiology

Volumn 280, Issue 6 49-6, 2001, Pages

  Zachary, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Endothelium; Kinase domain receptor; Nitric oxide; Prostacyclin

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN; PROTECTIVE AGENT; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

EID: 0034979275     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.2001.280.6.c1375     Document Type: Review

References (132)

1. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
2. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
3. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells
4. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
5. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins, occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors
6. Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro
7. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth muscle cells
8. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
9. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells
10. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation
11. 2+ and von Willebrand factor release in human endothelial cells
12. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
13. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
14. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells
15. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumour cell expression, and high affinity binding to Flk-1/KDR
16. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
17. Role of tissue factor in embryonic blood vessel development
18. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries
19. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
20. The vascular endothelial growth factor receptor Flt-1 mediates biological activities
21. Human vascular permeability factor. Isolation from U937 cells
22. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress
23. Differential regulation of extracellular signal-regulated kinases (ERK) 1 and 2 by cyclic AMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells
24. Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity
25. 2+ mobilization in human umbilical vein endothelial cells
26. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase
27. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
28. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism
29. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
30. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
31. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases
32. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor
33. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
34. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
35. Vascular endothelial growth factor
36. 2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress
37. Angiogenesis in cancer, vascular, rheumatoid and other diseases
38. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
39. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in Flt1 knock-out mice
40. Control of adhesion-dependent cell survival by focal adhesion kinase
41. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
42. Dynamic activation of endothelial nitric oxide synthase by Hsp 90
43. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1
44. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
45. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
46. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway
47. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: Results of a randomised placebo controlled trial
48. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration
49. 2+
50. Nitric oxide modulation of focal adhesions in endothelial cells
51. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains
52. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src
53. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
54. Therapeutic angiogenesis
55. 3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
56. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells signals endothelial cell production of nitric oxide
57. VEGF up-regulates ecNOS message, protein, and NO production in human endothelial cells
58. Vascular endothelial growth factor/vascular permeability factor produces nitric-oxide dependent hypotension
59. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis
60. Therapeutic angiogenesis for heart failure
61. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
62. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
63. Requirement for neuropilin-1 in embryonic vessel formation
64. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
65. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
66. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice
67. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
68. A novel function of the vascular endothelial growth factor receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells
69. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
70. Nitric oxide: An endogenous modulator of leukocyte adhesion
71. Gene transfer into the carotid artery using an adventitial collar: Comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses
72. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries
73. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts
74. Placenta growth factor stimulates MAP kinase and mitogenicity, but not phospholipase C-γ and migration of endothelial cells expressing Flt-1
75. FAK and disassembly of focal adhesions in human endothelial cell apoptosis
76. Characterization of signal transduction pathways in human bone marrow endothelial cells
77. Nuclear localization and apoptotic regulation of an amino-terminal domain focal adhesion kinase (FAK) fragment in endothelial cells
78. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
79. High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
80. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
81. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
82. Tissue factor and hemostasis
83. Vascular endothelial growth factor (VEGF) and its receptors
84. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells
85. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury
86. Vascular endothelial growth factor B (VEGF-B), binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
87. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
88. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular-signal-regulated kinase1/2 activation in postcapillary endothelium
89. Endothelial growth factor receptors in human fetal heart
90. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
91. Signalling via vascular endothelial growth factor receptors
92. 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
93. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
94. Receptor chimeras indicate that the vascular endothelial growth factor receptor 1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells
95. Induction of macrophage VEGF in response to oxidised LDL and VEGF accumulation in human atherosclerotic lesions
96. Mechanisms of angiogenesis
97. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
98. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase
99. Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: Essential role of endothelium-derived nitric oxide
100. NO at work
101. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
102. VEGF modulates NO production: The basis of a cytoprotective effect?
103. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
104. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and protein kinase C signalling pathway
105. Molecular mechanisms linking thrombosis and angiogenesis in cancer
106. Food for starving hearts
107. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
108. 3 integrin in the activation of vascular endothelial growth factor receptor-2
109. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
110. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells
111. Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor in vascular smooth muscle cells
112. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 cells
113. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEKMAP kinase pathway for DNA synthesis in primary endothelial cells
114. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
115. The role of phosphatidylinositol 3′-kinase in vascular endothelial growth factor signalling
116. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity
117. Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells
118. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
119. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs
120. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
121. Different signal transduction properties of Kdr and Flt-1, two receptors for vascular endothelial growth factor
122. Vascular endothelial growth factor up-regulates the expression of matrix metalloproteinases in vascular smooth muscle cells. Role of Flt1
123. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
124. The proliferative effect of vascular endothelial growth factor requires protein kinase C-α and protein kinase C-ζ
125. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo
126. 2 in endothelial cells via p42/p44 mitogen activated protein kinases
127. 2), prostaglandin E1 and D2 on platelet aggregation in different species
128. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischaemia
129. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
130. Vascular protection: A novel, non-angiogenic cardiovascular role for vascular endothelial growth factor
131. FAK): A point of convergence in the action of neuropeptides, integrins and oncogenes
132. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis